Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Succession Planning Targeted In House Legislation

Executive Summary

Hamburg’s departure from commissioner post seems to be proceeding smoothly; proposals in 21st Century Cures bill would mandate a similar process always be followed.

You may also be interested in...



Califf Nomination Adds New Dynamic, Maybe New Provisions, To FDA Reform Bills

Senate legislation may be influenced by movement to push through Califf’s nomination for FDA commissioner.

Putting Patients In Charge Of Drug Development. Like CEO In Charge

FDA, PhRMA and BIO leadership could look considerably different under a modest proposal from National Health Council's Marc Boutin.

House Trims 21st Century Cures Fat: Draft Bill Loses Half Its Weight

New discussion draft drops controversial exclusivity extensions and some other lesser-known ideas that may have benefited FDA and sponsors, but some placeholders still need to be filled.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS056649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel